Logothetis CJ - Search Results

1

Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells.

Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG. Subbarayan V, et al. Among authors: logothetis cj. Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1710-6. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15533897

2

Establishment of two human prostate cancer cell lines derived from a single bone metastasis.

Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Navone NM, et al. Among authors: logothetis cj. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2493-500. Clin Cancer Res. 1997. PMID: 9815652

3

Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma.

Kim J, Logothetis CJ. Kim J, et al. Among authors: logothetis cj. Urol Clin North Am. 1999 May;26(2):281-90. doi: 10.1016/s0094-0143(05)70068-9. Urol Clin North Am. 1999. PMID: 10361551 Review.

4

TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.

Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. Navone NM, et al. Among authors: logothetis cj. Clin Cancer Res. 2000 Mar;6(3):1190-7. Clin Cancer Res. 2000. PMID: 10741751

5

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Tu SM, et al. Among authors: logothetis cj. Lancet. 2001 Feb 3;357(9253):336-41. doi: 10.1016/S0140-6736(00)03639-4. Lancet. 2001. PMID: 11210994 Clinical Trial.

6

Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway.

Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. Yang J, et al. Among authors: logothetis cj. Cancer Res. 2001 Jul 15;61(14):5652-9. Cancer Res. 2001. PMID: 11454720

7

Fingerprinting the circulating repertoire of antibodies from cancer patients.

Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Mintz PJ, et al. Among authors: logothetis cj. Nat Biotechnol. 2003 Jan;21(1):57-63. doi: 10.1038/nbt774. Epub 2002 Dec 23. Nat Biotechnol. 2003. PMID: 12496764

8

Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study.

Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Kim J, et al. Among authors: logothetis cj. Urol Oncol. 2003 Jan-Feb;21(1):21-6. doi: 10.1016/s1078-1439(02)00207-7. Urol Oncol. 2003. PMID: 12684123 Clinical Trial.

9

Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.

Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Fizazi K, et al. Among authors: logothetis cj. Clin Cancer Res. 2003 Jul;9(7):2587-97. Clin Cancer Res. 2003. PMID: 12855635

10

Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP).

Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Tu SM, et al. Among authors: logothetis cj. Urol Oncol. 2003 Sep-Oct;21(5):342-8. doi: 10.1016/s1078-1439(02)00300-9. Urol Oncol. 2003. PMID: 14670540

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

423 results

Search Page

Filters